Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (0), the stock would be worth GBX-0.05 (103% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.9 | GBX1.95 |
0%
|
| Industry Average | 0 | GBX-0.05 |
-103%
|
| Country Average | 0 | GBX-0.04 |
-102%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
8.5m GBP | -0.9 | -0.6 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 21.9 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
26.8B USD | 20.4 | 29.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.9B AUD | 77.5 | 62.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 10.2 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.8B SEK | -133.5 | 96.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.9B USD | 15.2 | 42.3 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 14.9 | 18.8 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 267.9 | -328 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
18.6B CNY | -118 | -60.4 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.8B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
